Project description DEENESFRITPL Mixed reality innovation helping stroke patients on the road to rehabilitation Stroke is the most common cause of long-term disability world-wide, and innovations are key to improving access to effective screening, diagnostics and treatment, and to following the EU's Action Plan for Stroke. There are millions of stroke victims each year that need effective individualised treatment which can be achieved by using the innovative products from the Swedish company, BRAIN STIMULATION AB. RehAtt® is a method based on the latest neuroscience technology, now available using smart glasses. It can be used at home after discharge to improve function, independence and quality of life, through fun, motivating and stimulating 3D games in Mixed Reality. The EU-funded project HARPER will help pave the way for the innovative products' entry into the global market. Show the project objective Hide the project objective Objective Brain Stimulation AB is a Swedish SME started in 2011 with the aim of exploiting brain plasticity results from research withina new concept of rehabilitation and diagnosis of cognitive impairments of attention in stroke patients (the NeglectSyndrome). We address the global challenge of rehabilitating patients with cognitive and upper limb problems from Stroke,Dementia, Traumatic Brain Injuries, Parkinson and other degenerative brain diseases. Cognitive impairments as in theNeglect Syndrome is not discovered nor treated in suitable time and the normal hospital stay is too short to rehabilitate thepatients properly. Our innovation meets the need of early detection and diagnosis as well as efficient rehabilitation ofpatients in clinics and that can continue in patients’ home environment. If the Neglect Syndrome is discovered and treatedfaster and better than today, the wellbeing of patients will increase. The burden and the costs for their care will besignificantly reduced. Around 30% of the 16 Million new stroke patients worldwide per year suffer from the NeglectSyndrome i.e. there are 5-6 million new patients per year. Our addressable market exceeds 6 Million patients per year as ourambition is to reach not just the stroke patients with Neglect Syndrome but also Dementia, Traumatic Brain Injuries,Parkinson and other degenerative brain diseases. The innovation project will lead to a generation of €10,3 Million in turnoverand creating 40 new job positions in a five-year perspective after market-launch as well as creating IP rights from theoutcome of the Project. The goal is to develop, verify and bring our innovation towards global market launch. We will gofrom TRL 6 towards TRL 9 during the full innovation project life cycle. There will be sustainable effects in economic, ecologicand social terms for effective cognitive rehabilitation performed in people’s homes, with therapist support through e-healthsolutions, when needed. Fields of science medical and health scienceshealth scienceshealth care serviceseHealthmedical and health sciencesclinical medicinephysiotherapymedical and health sciencesbasic medicineneurologydementiamedical and health sciencesbasic medicineneurologystrokemedical and health sciencesbasic medicineneurologyparkinson Programme(s) H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs Main Programme H2020-EU.3. - PRIORITY 'Societal challenges H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies Topic(s) EIC-SMEInst-2018-2020 - SME instrument Call for proposal H2020-EIC-SMEInst-2018-2020 See other projects for this call Sub call H2020-SMEInst-2018-2020-1 Funding Scheme SME-1 - SME instrument phase 1 Coordinator BRAIN STIMULATION AB Net EU contribution € 50 000,00 Address Lovoudden 619 913 33 Holmsund Sweden See on map Region Norra Sverige Övre Norrland Västerbottens län Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 21 429,00